Elanco Animal Health (NYSE:ELAN) Announces Quarterly Earnings Results, Beats Expectations By $0.07 EPS

Key Points

• Elanco reported quarterly EPS of $0.27, beating the $0.20 consensus, while revenue rose 11.3% year over year to $1.26 billion and exceeded expectations.
• The company raised its 2026 adjusted EPS guidance to $1.17–$1.20. Innovation-product revenue increased 40% to $328 million, and adjusted gross margin expanded 300 basis points to 56.1%.
• Management expects fourth-quarter organic growth to moderate to 4%–6% and noted potential 2027 headwinds, including Costco’s non-renewal, inflation and initially dilutive Befrena growth.

Elanco Animal Health (NYSE:ELAN - Get Free Report) issued its earnings results on Friday. The company reported $0.27 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.20 by $0.07, FiscalAI reports. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The firm had revenue of $1.26 billion for the quarter, compared to analysts' expectations of $1.21 billion. During the same quarter last year, the company posted $0.19 earnings per share. Elanco Animal Health's revenue was up 11.3% on a year-over-year basis. Elanco Animal Health updated its Q4 2026 guidance to 0.160-0.190 EPS and its FY 2026 guidance to 1.170-1.200 EPS.

Here are the key takeaways from Elanco Animal Health's conference call:

• Elanco reported 11% revenue growth in Q3, or 9% organic constant currency, and exceeded its guidance for revenue, adjusted EBITDA and adjusted EPS. The company raised full-year 2026 guidance, including adjusted EPS to $1.17–$1.20.
• Innovation products powered growth: Q3 innovation revenue rose 40% to $328 million, led by Zenrelia and Credelio Quattro, with both reaching record U.S. market share in September. Elanco raised its 2026 innovation revenue target to $1.275 billion and expects Befrena to be a significant U.S. Pet Health growth driver in 2027.
• Adjusted gross margin expanded 300 basis points to 56.1%, while the company generated $362 million in year-to-date free cash flow and reduced net leverage to 2.9 times. Management said productivity initiatives and growing innovation sales support further margin improvement.
• Management expects Q4 organic growth to moderate to 4%–6%, and flagged 2027 offsets including Costco’s non-renewal, regional farm-animal cycles, persistent inflation and initially dilutive Befrena growth. Elanco nevertheless reiterated its 2027 growth algorithm and expects pet health to outperform farm animal.
• Executives described competition as generally responsible but noted targeted promotions and corporate-account offers in parts of the market. They said these tactics may shift sales timing, but maintained that they do not expect a material change to the trajectory of share gains.

Elanco Animal Health Price Performance

NYSE:ELAN traded up $1.97 during trading hours on Friday, reaching $25.65. 11,505,379 shares of the company's stock were exchanged, compared to its average volume of 4,744,676. The company has a quick ratio of 1.10, a current ratio of 2.05 and a debt-to-equity ratio of 0.58. The company has a market capitalization of $12.81 billion, a P/E ratio of -62.55, a price-to-earnings-growth ratio of 2.14 and a beta of 1.73. Elanco Animal Health has a 12 month low of $19.40 and a 12 month high of $27.98. The business's 50-day simple moving average is $23.13 and its two-hundred day simple moving average is $23.82.

Insider Buying and Selling

In other news, insider Timothy J. Bettington sold 4,350 shares of the business's stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $23.00, for a total transaction of $100,050.00. Following the sale, the insider directly owned 138,911 shares of the company's stock, valued at $3,194,953. The trade was a 3.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Michael J. Harrington bought 5,000 shares of Elanco Animal Health stock in a transaction dated Wednesday, August 12th. The shares were bought at an average cost of $21.82 per share, with a total value of $109,100.00. Following the completion of the acquisition, the director owned 131,451 shares of the company's stock, valued at $2,868,260.82. The trade was a 3.95% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 48,998 shares of company stock worth $1,139,373 over the last quarter. 1.14% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on ELAN. Morgan Stanley dropped their price target on Elanco Animal Health from $26.00 to $25.00 and set an "equal weight" rating on the stock in a research report on Thursday, October 29th. KeyCorp restated an "overweight" rating on shares of Elanco Animal Health in a research note on Wednesday, September 30th. Jefferies Financial Group downgraded Elanco Animal Health from a "buy" rating to a "hold" rating and lowered their price objective for the stock from $31.00 to $24.00 in a research note on Tuesday, October 20th. UBS Group raised their target price on Elanco Animal Health from $31.00 to $33.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. Finally, Weiss Ratings raised shares of Elanco Animal Health from a "sell (d)" rating to a "sell (d+)" rating in a report on Friday, September 4th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $29.33.

Key Headlines Impacting Elanco Animal Health

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: Third-quarter adjusted EPS was $0.27, ahead of the $0.20 consensus, while revenue rose 11% year over year to $1.265 billion, topping estimates. Elanco also reported 9% organic constant-currency growth and gross-margin expansion. Read More.
• Positive Sentiment: Elanco raised its 2026 adjusted EPS outlook to $1.17–$1.20, versus the $1.13 consensus, and revenue guidance to $5.155–$5.18 billion, above the $5.1 billion consensus. It also lifted its innovation revenue target and improved its year-end net-leverage target to about 2.9x adjusted EBITDA. Read More.
• Positive Sentiment: Company survey findings offered further demand support: 93% of pet owners surveyed said they maintained or increased pet spending in the prior three months despite cost pressures. Read More.
• Neutral Sentiment: Fourth-quarter adjusted EPS guidance of $0.16–$0.19 brackets the $0.18 consensus, while revenue guidance of $1.2 billion matches estimates. Elanco’s early 2027 outlook calls for growth broadly in line with its previously stated long-term targets, rather than a further acceleration. Read More.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio is designed to help prevent and treat disease, control parasites and support the health and productivity of animals.

The company's products include vaccines, parasiticides, antibiotics, nutritional supplements and other prescription and over-the-counter therapies. Its companion animal offerings address conditions such as flea and tick infestations, internal parasites, osteoarthritis and dermatological disorders, while its farm animal products support the health of cattle, poultry, swine and aquaculture species.

Elanco serves customers in markets around the world through relationships with veterinarians, animal owners, livestock producers, retailers and distributors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.